A novel study from Karolinska Institutesuggests that RAS-antagonists, common drugs for patients with heart failure, may benefit also patients who have concomitant kidney disease, a group previously not studied. These drugs have proven effect in heart failure, but patients with kidney disease were exc...
Thus, antithrombotic therapy would be expected to provide a substantial morbidity and mortality benefit to these patients. However, clinical evidence to support this hypothesis is limited and inconsistent. Aspirin is routinely used in patients with CHF secondary to ischaemic heart disease; however, as ...
Biological effects of aldosterone: Salt retention Myocardial fibrosis Reduced myocardial norepinephrine uptake Treatment with spironolacton is associated with mortality benefit in patients with heart failure (~30% reduction) Vasodilators Vasodilators may improve symptoms in heart failure Most vasodilator can ...
et al. Right ventricular function and sexual function: exploring shadows in male and female patients with heart failure. J. Sex. Med. 16, 1199–1211 (2019). PubMed Google Scholar Gandaglia, G. et al. A systematic review of the association between erectile dysfunction and cardiovascular ...
Most fatalities appeared to result from cardiovascular-related events (e.g., heart failure, sudden death) or infections (mostly pneumonia). Observational studies suggest that conventional or first-generation antipsychotic agents also may increase mortality in such patients. Antipsychotic agents, including ...
Heart Failure and EdemaFluid retention and edema reported.NSAIAs (selective COX-2 inhibitors, prototypical NSAIAs) may increase morbidity and mortality in patients with heart failure.NSAIAs may diminish cardiovascular effects of diuretics, ACE inhibitors, or angiotensin II receptor antagonists used to ...
摘要: Inotropic drugs have not, as yet, been shown in double-blind, randomised and placebo-controlled trials to be of value in the treatment of heart failure. There are theoretical reasons why inotropic drugs may initiate arrhythmias, worsen ischaemia and possibly even increase mortality....
Our objective was to evaluate which tyrosine kinase-targeting drugs are associated with greater risk for new-onset heart failure (HF). Methods: A nested case–control analysis was conducted within a cohort of 27 992 patients of Clalit Health Services, newly treated with a tyrosine kinase-...
Experts recommend that patients with type 2 diabetes mellitus who have established (or are at a high risk for) ASCVD, established kidney disease, or heart failure receive a GLP-1 receptor agonist or SGLT2 inhibitor with demonstrated cardiovascular disease benefit. In patients with these ...
Patients with type 2 diabetes mellitus (T2DM) are at high risk of heart failure. A summary of the effects of blood glucose-lowering drugs other than glitazones on the risk of heart failure in routine clinical practice is lacking. The objective of this study was to conduct a systematic revie...